Beutel Goodman & Co Ltd. Sells 177,824 Shares of Cencora, Inc. $COR

Beutel Goodman & Co Ltd. lowered its position in Cencora, Inc. (NYSE:COR) by 34.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 332,952 shares of the company’s stock after selling 177,824 shares during the period. Beutel Goodman & Co Ltd. owned approximately 0.17% of Cencora worth $99,835,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Baader Bank Aktiengesellschaft grew its position in shares of Cencora by 318.5% during the 2nd quarter. Baader Bank Aktiengesellschaft now owns 4,336 shares of the company’s stock valued at $1,300,000 after acquiring an additional 3,300 shares during the period. Voleon Capital Management LP acquired a new position in shares of Cencora during the 1st quarter worth approximately $3,111,000. Focus Partners Wealth lifted its position in shares of Cencora by 25.8% during the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after buying an additional 1,171 shares in the last quarter. Acadian Asset Management LLC grew its stake in Cencora by 947.5% in the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after acquiring an additional 232,539 shares during the period. Finally, Martin Capital Partners LLC increased its holdings in Cencora by 205.2% in the 2nd quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after acquiring an additional 2,544 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on COR shares. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Evercore ISI set a $400.00 price target on Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. Mizuho lifted their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings cut shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday. Finally, JPMorgan Chase & Co. lifted their target price on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $371.09.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the completion of the sale, the chief executive officer owned 65,746 shares in the company, valued at approximately $24,105,113.44. This represents a 7.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 46,640 shares of company stock valued at $14,099,338 over the last ninety days. Corporate insiders own 10.80% of the company’s stock.

Cencora Stock Performance

Shares of COR stock opened at $337.43 on Friday. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 12 month low of $223.92 and a 12 month high of $377.54. The firm has a fifty day moving average price of $339.40 and a 200 day moving average price of $309.16. The company has a market cap of $65.42 billion, a P/E ratio of 42.44, a PEG ratio of 1.59 and a beta of 0.63.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The business had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. During the same quarter in the prior year, the business posted $3.34 EPS. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is presently 30.19%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.